Chia-Wei Yang, A. K. M. Atique Ullah, Xuefei Huang
experiments with an orthotopic breast cancer model demonstrated the superior tumor-targeting capability of G2-Sal-ICG and its ability to significantly suppress tumor growth. Our findings suggested G2-Sal-ICG is a promising theranostic nanodrug for CD44-targeted therapy, combining efficient drug delivery with real-time non-invasive imaging, thus highlighting its potential for clinical applications in breast cancer treatment.